All You Need To Know About-Juvenile Diabetes-Chesapeake-Prevent Diabetes
Full list of Video Credits is stored here http://broadcaster.beazil.net/public/credits/youtube/videos/41954 Living with T1D is a constant balancing act. People with T1D must regularly monitor their blood-sugar level, inject or continually infuse insulin through a pump, and carefully balance their insulin doses with eating and daily activities throughout the day and night.
T1D is a serious and stressful disease to manage. Treatment options are improving all the time, and people with T1D are able to lead normal, productive and inspiring lives. JDRF is driving research to improve the technology people with T1D use to monitor blood-sugar levels and deliver the proper doses of insulin, as well as research that will ultimately deliver a cure. But even with intensive disease management, a significant portion of their day is still spent with high or low blood-sugar levels, placing people with T1D at risk for devastating complications such as heart attack, stroke, blindness, kidney disease and amputation. The Health Care and Social Assistance industry includes establishments and services such as:
hospitals, nursing and residential care facilities and out-patient care centres; offices of health practitioners (i.e. dentists, doctors, optometrists and chiropractors); medical and diagnostic laboratories; home health care services; ambulance services; social assistance services (i.e. for children, youth, the elderly, families); community food, housing, emergency and relief services; vocational rehabilitation services; and daycare services JDRF prioritizes its funding for type 1 diabetes research in four interrelated therapeutic areas: autoimmune therapies, β-cell therapies, prevention of complications, and glucose control. Each therapeutic area encompasses a diverse portfolio of research programs that span from exploratory to preclinical proof-of-principle and on to clinical proof-of-concept research. The organization’s overarching strategy focuses on addressing critical gaps and challenges, catalyzing innovative and transformational research, advancing and translating research, creating collaborations, and accelerating time lines at all stages of research development. To facilitate downstream partnering and follow-on funding, JDRF increasingly supports product development by “de-risking” projects, thereby decreasing the barriers of entry for future funders. In 1963, the new independent city of Chesapeake was created when the former independent city of South Norfolk consolidated with Norfolk County. The consolidation, authorized by the Virginia General Assembly, was approved and the new name selected by the voters of each communities by referendum. The new city joined the ranks of the current Seven Cities of Hampton Roads which are linked by the circumferential Hampton Roads Beltway. Formed in 1691 in the Virginia Colony, Norfolk County had originally included essentially all the area which became the towns and later cities of Norfolk, Portsmouth, and South Norfolk, but had seen its area frequently reduced as these cities added territory through annexations after 1871. JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D. JDRF has led the search for a cure for T1D since our founding in 1970. In those days, people commonly called the disease “juvenile diabetes” because it was frequently diagnosed in, and strongly associated with, young children. Our organization began as the Juvenile Diabetes Foundation. Later, to emphasize exactly how we planned to end the disease, we added a word and became the Juvenile Diabetes Research Foundation.Today, we know an equal number of children and adults are diagnosed every day—approximately 110 people per day.
This is all about –
Education,Microvascular Complications,T1D damage,Type 1,Diabetes and Pregnancy,HAPO Study,Juvenile diabetes foundation,Veterans Affairs Diabetes Trial,TypeOneNation,Blood Glucose Level,sugar diabetes,insulin pumps,Random Plasma Glucose Test,children diabetes,World diabetes day,glyburide,miglitol,noninsulin monotherapy,NPH Humulin N,Cure,Derek Rapp,diabetic mastopathy,A1C complications,rapid insulin injection,insulin receptors,Oral Glucose Tolerance Test,treatment of diabetes,alpha-glucosidase inhibitor,blood glucose monitoring,Advocacy,engage,The Action to Control Cardiovascular Risk in Diabetes Study,Promise Gala,Top Research Highlights,permanent insulinopenia,T1D Team,ketosis,diabetes diagnosis,negative diabetes associated autoantibodies,metformin,SDP,T1D Community,Juvenile Diabetes charity,injection site rotation,Hypers,UKPDS Study,Juvenile Diabetes Research Foundation,plasma glucose criteria,Treatment Advocacy,Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation Trial,estimated average glucose,Children’s Congress,Jump to cure.